Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: Cost-effectiveness analysis

Radiology

Volumn 248, Issue 1, 2008, Pages 169-178

  Pandharipande, Pari V ^a   Gervais, Debra A ^a   Mueller, Peter R ^a   Hur, Chin ^a   Gazelle, G Scott ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LIFE EXPECTANCY; MALE; NEPHRON SPARING SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; SENSITIVITY ANALYSIS; THERAPY EFFECT; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; KIDNEY TUMOR; MINIMALLY INVASIVE SURGERY; MORTALITY; NEPHRECTOMY; SALARY AND FRINGE BENEFIT; STATISTICAL MODEL; STATISTICS; SURVIVAL; SURVIVAL RATE; UNITED STATES;

CARCINOMA, RENAL CELL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; KIDNEY NEOPLASMS; MASSACHUSETTS; MODELS, ECONOMIC; NEPHRECTOMY; SALARIES AND FRINGE BENEFITS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 47249120728     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2481071448     Document Type: Article

References (49)

1. American Cancer Society. Cancer facts and 2007 figures 2007. Atlanta, Ga: American Cancer Society, 2007.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-1631.
3. Devesa SS, Silverman DT, McLaughlin JK, Brown CC, Connelly RR, Fraumeni JF Jr. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1990;1:133-141.
4. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;51:203-205.
5. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331-1334.
6. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173:1889-1892.
7. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001;166:6-18.
8. Novick AC. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med 2002;53:393-407.
9. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. II. Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005;185:72-80.
10. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. I. Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005;185:64-71.
11. McDougal WS, Gervais DA, McGovern FJ, Mueller PR. Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol 2005;174:61-63.
12. Schiller JD, Gervais DA, Mueller PR. Radiofrequency ablation of renal cell carcinoma. Abdom Imaging 2005;30:442-450.
13. Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007;189:429-436.
14. Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ. Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. AJR Am J Roentgenol 2003;180:1503-1508.
15. Breen DJ, Rutherford EE, Stedman B, et al. Management of renal tumors by image-guided radiofrequency ablation: experience in 105 tumors. Cardiovasc Intervent Radiol 2007;30:936-942.
16. Lotan Y, Cadeddu JA. A cost comparison of nephron-sparing surgical techniques for renal tumour. BJU Int 2005;95:1039-1042.
17. Kletscher BA, Qian J, Bostwick DG, Andrews PE, Zincke H. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol 1995;153:904-906.
18. Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995;45:34-40; discussion 40-41.
19. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 1996;155:1868-1873.
20. Manikandan R, Srinivasan V, Rane A. Which is the real gold standard for small-volume renal tumors? radical nephrectomy versus nephron-sparing surgery. J Endourol 2004;18:39-44.
21. McAchran SE, Lesani OA, Resnick MI. Radiofrequency ablation of renal tumors: past, present, and future. Urology 2005;66:15-22.
22. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22:417-430.
23. Goldman L. Cost-effectiveness in a flat world: can ICDs help the United States get rhythm? N Engl J Med 2005;353:1513-1515.
24. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005;353:1516-1522.
25. Gillick MR. Medicare coverage for technological innovations: time for new criteria? N Engl J Med 2004;350:2199-2203.
26. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258.
27. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
28. Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology 2004;233:729-739.
29. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650-1657.
30. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005;23:423-432.
31. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342.
32. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-677.
33. Ries LAG, Harkins D, Krapcho M, et al, eds. SEER cancer statistics review, 1975-2003. Bethesda, Md. National Cancer Institute. http://seer.cancer. gov/csr/1975-2003/. Published November 2005. Accessed April, 2006.
34. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-458.
35. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-888.
36. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982;73:889-897.
37. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000;164:322-325.
38. Surveillance Epidemiology and End Results (SEER) Program Public-Use Data, 1973-2004. Bethesda, Md. National Cancer Institute. http://seer.cancer.gov/ data/. Published April 2006. Accessed April, 2007.
39. Centers for Disease Control, National Center for Health Statistics. LEWK3 United States Life Tables 1999-2003. http://www.cdc.gov/nchs/datawh/statab/ unpubd/mortabs/lewk3-10.htm. Accessed April, 2006.
40. Shekarriz B, Upadhyay J, Shekarriz H, et al. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. Urology 2002;59:211-215.
41. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-426.
42. Chang I, Mikityansky I, Wray-Cahen D, Pritchard WF, Karanian JW, Wood BJ. Effects of perfusion on radiofrequency ablation in swine kidneys. Radiology 2004;231:500-505.
43. Yamakado K, Nakatsuka A, Kobayashi S, et al. Radiofrequency ablation combined with renal arterial embolization for the treatment of unresectable renal cell carcinoma larger than 3.5 cm: initial experience. Cardiovasc Intervent Radiol 2006;29:389-394.
44. Johnson DB, Solomon SB, Su LM, et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. J Urol 2004;172:874-877.
45. Onishi T, Nishikawa K, Hasegawa Y, et al. Assessment of health-related quality of life after radiofrequency ablation or laparoscopic surgery for small renal cell carcinoma: a prospective study with medical outcomes Study 36-Item Health Survey (SF-36). Jpn J Clin Oncol 2007;37:750-754.
46. Matin SF, Gill IS, Worley S, Novick AC. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm. or less renal tumor with a normal contralateral kidney. J Urol 2002;168:1356-1359.
47. Weld KJ, Venkatesh R, Huang J, Landman J. Evolution of surgical technique and patient outcomes for laparoscopic partial nephrectomy. Urology 2006;67:502-506.
48. Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. BJU Int 2007;99:1265-1270.
49. Hafron J, Kaouk JH. Ablative techniques for the management of kidney cancer. Nat Clin Pract Urol 2007;4:261-269.